Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus ...

Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...

Lupkynis is a medicine that is used for a specific kidney disease called lupus nephritis. Lupus nephritis is a kidney condition that affects people with systemic lupus erythematosus (SLE). SLE is an ...

A regulatory decision is expected by October 2025. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva ®) for the ...

Objective Macrophages and kidney cell pyroptosis/ferroptosis could play an important role in the pathogenesis of lupus ...

Please provide your email address to receive an email when new articles are posted on . HUNTINGTON BEACH, Calif. — Non-nephritis lupus and lupus nephritis may actually be part of a spectrum of ...

Please provide your email address to receive an email when new articles are posted on . Current treatment paradigms for lupus nephritis offer significant room for improvement, according to a presenter ...

A retrospective study compared cardiovascular risks among patients with SLE who did and did not develop lupus nephritis and/or antiphospholipid antibody-positivity over time.

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License ...

Objective To investigate the relationship between adverse childhood experiences (ACEs) and health outcomes in childhood-onset ...